nach oben

Journal of Endocrinological Investigation

Erschienen in:

01.02.2022 | Original Article

Genotypic spectrum of 21-hydroxylase deficiency in an endogamous population

verfasst von: R. A. A. Mahmoud, N. H. Amr, N. N. Toaima, T. M. Kamal, H. H. Elsedfy

Erschienen in: Journal of Endocrinological Investigation | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten

Abstract

Background

Congenital adrenal hyperplasia (CAH) due to autosomal recessive 21-hydroxylase deficiency (21-OHD) is caused by defects in the CYP21 (CYP21A2) gene. Several mutations have been identified in the CYP21 (CYP21A2) gene of patients with 21-OHD. We aimed at determining the frequency of these mutations among a group of Egyptian patients and studying the genotype–phenotype correlation.

Methods

Forty-seven patients with CAH due to 21-OHD from 42 different families diagnosed by clinical and hormonal evaluation and classified accordingly into salt wasting (SW) and simple virilizing (SV) phenotypes were enrolled. Their ages ranged between 1.78 and 18.99 years. Molecular analysis of the CYP21 (CYP21A2) gene was performed for the detection of eleven common mutations: P30L, I2 splice (I2 G), Del 8 bp E3 (G110del8nt), I172N, cluster E6 (I236N, V237E, M239K), V281L, L307 frameshift (F306 + T), Q318X, R356W, P453S, R483P by polymerase chain reaction (PCR) and reverse hybridization.

Results

Disease-causing mutations were identified in 47 patients, 55.31% of them were compound heterozygous. The most frequent mutations were I2 splice (25.43%), followed by cluster E6 (16.66%) and P30L (15.78%). Two point mutations (P453S, R483P) were not identified in any patient. In the SW patients, genotypes were more compatible with their phenotypes.

Conclusion

Molecular characterization should be considered along with clinical and biochemical diagnosis of CAH since it could confirm the diagnosis, outline the treatment strategy and morbidity, and ensure proper genetic counseling.

Merke DP, Bornstein SR (2005) Congenital adrenal hyperplasia. The Lancet 365(9477):2125–2136

Levy-Shraga Y, Pinhas-Hamiel O (2016) High 17-hydroxyprogesterone level in newborn screening test for congenital adrenal hyperplasia. BMJ Case Rep 2016:bcr2015213939PubMedPubMedCentral

Trapp CM, Oberfield SE (2012) Recommendations for treatment of nonclassic congenital adrenal hyperplasia (NCCAH): an update. Steroids 77(4):342–346PubMed

White PC, Speiser PW (2000) Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. ENDOCR REV 21(3):245–291PubMed

New MI, Lekarev O, Parsa A, Yuen TT, O’Malley B, Hammer GD (2013) Genetic steroid disorders. Academic Press, London

Olgemöller B, Roscher AA, Liebl B, Fingerhut R (2003) Screening for congenital adrenal hyperplasia: adjustment of 17-hydroxyprogesterone cut-off values to both age and birth weight markedly improves the predictive value. J Clin Endocrinol Metab 88(12):5790–5794PubMed

Németh S, Riedl S, Kriegshäuser G, Baumgartner-Parzer S, Concolino P, Neocleous V, Phylactou LA, Borucka-Mankiewicz M, Onay H, Tukun A, Oberkanins C (2012) Reverse-hybridization assay for rapid detection of common CYP21A2 mutations in dried blood spots from newborns with elevated 17-OH progesterone. Clin Chim Acta 24(414):211–214

Higashi Y, Yoshioka H, Yamane M, Gotoh O, Fujii-Kuriyama Y (1986) Complete nucleotide sequence of two steroid 21-hydroxylase genes tandemly arranged in human chromosome: a pseudogene and a genuine gene. Proc Natl Acad Sci 83(9):2841–2845PubMedPubMedCentral

White PC, New MI, Dupont BO (1986) Structure of human steroid 21-hydroxylase genes. Proc Natl Acad Sci 83(14):5111–5115PubMedPubMedCentral

10.

Forest MG (2004) Recent advances in the diagnosis and management of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Hum Reprod 10(6):469–485

11.

Speiser PW, Azziz R, Baskin LS, Ghizzoni L, Hensle TW, Merke DP et al (2010) A summary of the Endocrine Society clinical practice guidelines on congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency. Int J Pediatr Endocrinol 2010:1–5

12.

Amr NH, Mahmoud RA, Youssef O, Toaima NN, Elsedfy H (2021) Effect of long-term glucocorticoid therapy on cardiac functions in children with congenital adrenal hyperplasia. Clin Endocrinol (Oxf) 94(2):210–218

13.

Der PA (1954) Genitalbefund beim Pseudohermaphroditismus femininus des kongenitalen adrenogenitalen Syndroms: Morphologie, Haufigkeit, Entwicklung, und Vererbung der verschiedenen Genitalformen. Helv Paeditr Acta 9:231–248

14.

OMIM: www.ncbi.nlm.nih.gov/omim.

15.

Speiser PW, Dupont J, Zhu D, Serrat J, Buegeleisen M, Tusie-Luna MT et al (1992) Disease expression and molecular genotype in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Invest 90(2):584–595PubMedPubMedCentral

16.

Krone N, Braun A, Roscher AA, Knorr D, Schwarz HP (2000) Predicting phenotype in steroid 21-hydroxylase deficiency? Comprehensive genotyping in 155 unrelated, well defined patients from southern Germany. J Clin Endocrinol Metab 85(3):1059–1065PubMed

17.

Wedell A, Thilén A, Ritzén EM, Stengler B, Luthman H (1994) Mutational spectrum of the steroid 21-hydroxylase gene in Sweden: implications for genetic diagnosis and association with disease manifestation. J Clin Endocrinol Metab 78(5):1145–1152PubMed

18.

Elmougy F, Elsharkawy M, Hafez M, Atty SA, Baz H, Ibrahim A et al (2020) Genetic profiling of CAH Egyptian children: rapid guide to clinical interpretation of common mutations. J Clin Invest 1:1–1

19.

Al-Obaidi RG, Al-Musawi B, Al-Zubaidi MA, Oberkanins C, Németh S, Al-Obaidi YG (2016) Molecular Analysis of CYP21A2 gene mutations among Iraqi patients with congenital adrenal hyperplasia. Enzyme Res. https://doi.org/10.1155/2016/9040616CrossRefPubMedPubMedCentral

20.

Baş F, Kayserili H, Darendeliler F, Uyguner O, Günöz H, Apak MY et al (2009) CYP21A2 gene mutations in congenital adrenal Hyperplasia: genotype− phenotype correlation in Turkish children. J Clin Res Pediatr Endocrinol 1(3):116PubMedPubMedCentral

21.

Daggag H, Hiyesat D, Khawaja N et al (2011) Prevalence of congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency, in Jordanian sample pool,” in Proceedings of the Endocrine Society’s 93rd Annual Meeting & Expo, National Center for Diabetes Endocrinology and Genetics, Boston, Mass, USA, June 2011.

22.

Rabbani B, Mahdieh N, Ashtiani MT, Larijani B, Akbari MT, New M et al (2012) Mutation analysis of the CYP21A2 gene in the Iranian population. Genet Test Mol Biomark 16(2):82–90

23.

Kharrat M, Tardy V, M’Rad R, Maazoul F, Jemaa LB, Refaï M, Morel Y, Chaabouni H. (2004) Molecular genetic analysis of Tunisian patients with a classic form of 21-hydroxylase deficiency: identification of four novel mutations and high prevalence of Q318X mutation. J Clin Endocrinol Metab 89(1):368–374PubMed

24.

Stikkelbroeck NM, Hoefsloot LH, de Wijs IJ, Otten BJ, Hermus AR, Sistermans EA (2003) CYP21 gene mutation analysis in 198 patients with 21-hydroxylase deficiency in The Netherlands: six novel mutations and a specific cluster of four mutations. J Clin Endocrinol Metab 88(8):3852–3859PubMed

25.

Marino R, Ramirez P, Galeano J, Perez Garrido N, Rocco C, Ciaccio M, Warman DM, Guercio G, Chaler E, Maceiras M, Bergadá I (2011) Steroid 21-hydroxylase gene mutational spectrum in 454 Argentinean patients: genotype–phenotype correlation in a large cohort of patients with congenital adrenal hyperplasia. Clin Endocrinol 75(4):427–435

26.

Ishii T, Anzo M, Adachi M, Onigata K, Kusuda S, Nagasaki K. Mass Screening Committee Japanese Society for Pediatric Endocrinology Japanese Society for Mass Screening. Guidelines for diagnosis and treatment of 21-hydroxylase deficiency (2014) revision). Clin Pediatr Endocrinol 2015(24):77–105

27.

Chi DV, Tran TH, Nguyen DH, Luong LH, Le PT, Ta MH, Ngo HT, Nguyen MP, Le-Anh TP, Nguyen DP, Bui TH (2019) Novel variants of CYP21A2 in Vietnamese patients with congenital adrenal hyperplasia. Mol Genet Genom Med 7(5):e623

28.

Baumgartner-Parzer S, Witsch-Baumgartner M, Hoeppner W (2020) EMQN best practice guidelines for molecular genetic testing and reporting of 21-hydroxylase deficiency. Euro J Human Genetics 28(10):1341–1367

29.

Rodrigues TMB, Barra CB, Santos JLS, Goulart EMA, Ferreira AVM, Silva IN et al (2015) Cardiovascular risk factors and increased carotid intima-media thickness in young patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Arch Endocrinol Metab 59(6):541–547PubMed

30.

Abdullah MA, Saeed U, Abass A, Lubna K, Weam A, Ali AS et al (2012) Disorders of sex development among Sudanese children: 5-year experience of a pediatric endocrinology clinic. J Pediatr Endocrinol Metab 25:1065–1072PubMed

31.

Alshabab LI, Alebrahem A, Kaddoura A, Al-Fahoum S (2015) Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: A five-year retrospective study in the Children’s Hospital of Damascus, Syria. Qatar Med J 2015(1):11

32.

Sowande OA, Adejuyigbe O (2009) Management of ambiguous genitalia in ile ife, Nigeria: challenges and outcome. Afr J Paediatr Surg 6(1):14PubMed

33.

Tony Nengom J, Sap Ngo Um S, Chelo D, Mbono Betoko R, Boombhi J, Mouafo Tambo F et al (2017) Assessment of cardiac function in children with congenital adrenal hyperplasia: a case control study in Cameroon. BMC Pediatr 17(1):109PubMedPubMedCentral

34.

Wilson RC, Nimkarn S, Dumic M, Obeid J, Azar M, Najmabadi H, Saffari F, New MI (2007) Ethnic-specific distribution of mutations in 716 patients with congenital adrenal hyperplasia owing to 21-hydroxylase deficiency. Mol Genet Metab 90(4):414–421PubMedPubMedCentral

35.

Bobba A, Marra E, Giannattasio S, Iolascon A, Monno F, Di Maio S (1999) 21-hydroxylase deficiency in Italy: a distinct distribution pattern ofCYP21 mutations in a sample from southern Italy. J Med Genet 36(8):648–650PubMedPubMedCentral

36.

Riedl S, Röhl FW, Bonfig W, Brämswig J, Richter-Unruh A, Fricke-Otto S, Bettendorf M, Riepe F, Kriegshäuser G, Schönau E, Even G (2019) Genotype/phenotype correlations in 538 congenital adrenal hyperplasia patients from Germany and Austria: discordances in milder genotypes and in screened versus prescreening patients. Endocr Connect 8(2):86–94PubMedPubMedCentral

37.

Finkielstain GP, Chen W, Mehta SP, Fujimura FK, Hanna RM, Van Ryzin C et al (2011) Comprehensive genetic analysis of 182 unrelated families with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 96(1):E161–E172PubMed

38.

L’allemand D, Tardy V, Gruters A, Schnabel D, Krude H, Morel Y. (2000) How a patient homozygous for a 30-kb deletion of the C4-CYP 21 genomic region can have a nonclassic form of 21-hydroxylase deficiency. J Clin Endocrinol Metab 85(12):4562–4567PubMed

39.

Gomes LG, Huang N, Agrawal V, Mendonça BB, Bachega TA, Miller WL (2009) Extraadrenal 21-hydroxylation by CYP2C19 and CYP3A4: effect on 21-hydroxylase deficiency. J Clin Endocrinol Metab 94(1):89–95PubMed

40.

New MI, Abraham M, Gonzalez B, Dumic M, Razzaghy-Azar M, Chitayat D et al (2013) Genotype–phenotype correlation in 1,507 families with congenital adrenal hyperplasia owing to 21-hydroxylase deficiency. Proc Natl Acad Sci 110(7):2611–2616PubMedPubMedCentral

41.

Schulze E, Scharer G, Rogatzki A, Priebe L, Lewicka S, Bettendorf M, Hoepffner W, Heinrich UE, Schwabe U (1995) Divergence between genotype and phenotype in relatives of patients with the intron 2 mutation of steroid-21-hydroxylase. Endocr Res 21(1–2):359–364PubMed

42.

Witchel SF, Bhamidipati DK, Hoffman EP, Cohen JB (1996) Phenotypic heterogeneity associated with the splicing mutation in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 81(11):4081–4088PubMed

43.

Speiser PW, White PC (2003) Congenital adrenal hyperplasia. N Engl J Med 349(8):776–788PubMed

44.

Bidet M, Bellanné-Chantelot C, Galand-Portier MB, Tardy V, Billaud L, Laborde K, Coussieu C, Morel Y, Vaury C, Golmard JL, Claustre A. (2009) Clinical and molecular characterization of a cohort of 161 unrelated women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency and 330 family members. J Clin Endocrinol Metab 94(5):1570–1578PubMed

45.

Barbaro M, Soardi FC, Östberg LJ, Persson B, de Mello MP, Wedell A, Lajic S (2015) In vitro functional studies of rare CYP 21A2 mutations and establishment of an activity gradient for nonclassic mutations improve phenotype predictions in congenital adrenal hyperplasia. Clin Endocrinol (Oxf) 82(1):37–44

46.

Tusie-Luna MT, Speiser PW, Dumic M, New MI, White PC (1991) A mutation (Pro-30 to Leu) in CYP 21 represents a potential nonclassic steroid 21-hydroxylase deficiency allele. Mol Endocrinol 5(5):685–692PubMed

47.

Pignatelli DL, Carvalho BL, Palmeiro A, Barros A, Guerreiro S, Maçut D (2019) The complexities in genotyping of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Front Endocrinol 10:432

48.

Gurgov S, Bernabé KJ, Stites J, Cunniff CM, Lin-Su K, Felsen D, New MI, Poppas DP (2017) Linking the degree of virilization in females with congenital adrenal hyperplasia to genotype. Ann N Y Acad 1402(1):56–63

49.

Elmougy F, Sharaf S, Hafez M, Khattab A, Abou-Yousef H, Elsharkawy M et al (2018) CYP21A2 genetic profile in 14 Egyptian children with suspected congenital adrenal hyperplasia: a diagnostic challenge. Ann N Y Acad 1415(1):11–20

50.

Baumgartner-Parzer SM, Nowotny P, Waldhausl W, Vierhapper H (2003) A rare duplicated 21-hydroxylase haplotype and a de novo mutation: a family analysis. J Clin Endocrinol Metab 88(6):2794–2796PubMed

51.

Robins T. Functional and structural studies on CYP21 mutants in congenital adrenal hyperplasia. Institutionen för molekylär medicin/Department of Molecular Medicine; 2005 Nov 18.

52.

Parker EA, Hovanes K, Germak J, Porter F, Merke DP (2006) Maternal 21-hydroxylase deficiency and uniparental isodisomy of chromosome 6 and X results in a child with 21-hydroxylase deficiency and Klinefelter syndrome. Am J Med Genet A 140:2236–2240PubMed

53.

Khayat RG, Saxena PC (2000) Consanguinity and its effect on infant and child mortality in Egypt. Egypt J Med Hum Genet 1:207–213

54.

Shawky RM, El-Awady MY, Elsayed SM, Hamadan GE (2011) Consanguineous matings among Egyptian population. Egypt J Med Hum Genet 12:157–163

55.

Krone N, Arlt W (2009) Genetics of congenital adrenal hyperplasia. Best Pract Res Clin Endocrinol Metab 23(2):181–192PubMed

Titel: Genotypic spectrum of 21-hydroxylase deficiency in an endogamous population
verfasst von: R. A. A. Mahmoud
N. H. Amr
N. N. Toaima
T. M. Kamal
H. H. Elsedfy
Publikationsdatum: 01.02.2022
Verlag: Springer International Publishing
Erschienen in: Journal of Endocrinological Investigation / Ausgabe 2/2022
Elektronische ISSN: 1720-8386
DOI: https://doi.org/10.1007/s40618-021-01648-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2022

TPO antibody in euthyroid pregnant women and cognitive ability in the offspring: a focused review

Cardiac structural and functional abnormalities in primary hyperparathyroidism

Glucose control in home-isolated adults with type 1 diabetes affected by COVID-19 using continuous glucose monitoring

Total and free vitamin D metabolites in patients with primary hyperparathyroidism

2021 update on thyroid-associated ophthalmopathy